Astrazeneca boosts cardiovascular pipeline with licensing deal pharma Astrazeneca has struck a licensing agreement worth up to $2bn (£1.5bn) with China’s CPSC Pharmaceutical Group to develop a new cardiovascular drug, the company announced on Monday. The Anglo-Swedish pharmaceutical giant will pay $100m (£76.5) upfront, with additional milestone payments of up to $1.9bn (£1.4bn), to licence a preclinical small molecule aimed at treating dyslipidemia. [...]
Astrazeneca drags down the FTSE 100 following mixed cancer trial results pharma Shares in Astrazenca and Daiichi Sankyo nose dived today after the pair revealed mixed results in their lung cancer drug's late-stage trial.
British Patient Capital invests £90m London biotech company Tech British Patient Capital recently also invested £10m into biotech firm Curve Therapeutics to support its cancer drug discovery technology.
Based in an old Bermondsey biscuit factory, this London cancer drug firm just raised millions May 21, 2024 Founded in 2012 by a PhD student, Labgenius uses technology to create more effective and safer antibodies for cancer treatment.
US regulator accepts GSK’s application to expand treatment of cancer drug April 24, 2024 The treatment, Jemperli, will now be classed as being able to help all adult patients with primary advanced or recurrent endometrial cancer. It is used alongside chemotherapy.